Uplizna FDA Approval History
Last updated by Judith Stewart, BPharm on April 14, 2025.
FDA Approved: Yes (First approved June 11, 2020)
Brand name: Uplizna
Generic name: inebilizumab-cdon
Dosage form: Injection
Company: Viela Bio
Treatment for: Neuromyelitis Optica Spectrum Disorder, Immunoglobulin G4-Related Disease
Uplizna (inebilizumab-cdon) is a CD19-directed cytolytic antibody used for the treatment of neuromyelitis optica spectrum disorder and immunoglobulin G4-related disease.
- Uplizna is indicated for the treatment of:
- neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
- immunoglobulin G4-related disease (IgG4-RD) in adult patients.
Development timeline for Uplizna
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.